FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Zolinza (vorinostat) by Merck Sharp & Dohme LLC to update/expand its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Zolinza (vorinostat)

Snippet

SUPPL AP for ZOLINZA (VORINOSTAT)